store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
INCB054329 是一种结构不同的溴结构域和末端外结构域 (BET) 抑制剂,可抑制 BRD2-BD1、BRD2-BD2、BRD3-BD1、BRD3-BD2、BRD4-BD1、BRD4-BD2、BRDT-BD1 和 BRDT-BD2,IC50 值为 分别为 44 nM、5 nM、9 nM、1 nM、28 nM、3 nM、119 nM 和 63 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 647 | 现货 | ||
5 mg | ¥ 1,570 | 现货 | ||
10 mg | ¥ 2,490 | 现货 | ||
25 mg | ¥ 4,230 | 现货 | ||
50 mg | ¥ 5,910 | 现货 | ||
100 mg | ¥ 8,330 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,730 | 现货 |
产品描述 | INCB054329, a structurally distinct bromodomain and extraterminal domain (BET) inhibitor, inhibits BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2 with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM respectively. |
靶点活性 | BRD2 BD2:5 nM, BRD3 BD2:1 nM, BRD4 BD1:28 nM, BRD4 BD2:3 nM, BRD3 BD1:9 nM |
体外活性 | INCB054329 shows no significant inhibitory activity against 16 non-BET bromodomains at 3 μM. In a panel of 32 hematologic cancer cell lines derived from acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma, the GI50 of INCB054329 is 152 nM (range, 26-5000 nM). In contrast to tumor cell lines, the GI50 against T cells isolated from non-diseased donors stimulated ex vivo with IL-2 is 2.435 μM. Growth inhibition correlates with a concentration-dependent accumulation of cells in the G1 phase of the cell cycle. INCB054828 is also a selective kinase inhibitor of the FGFR 1, 2, and 3[1]. Treatment with INCB054329 inhibits expression of c-MYC and induced HEXIM1 in myeloma cell lines. In both lymphoma and AML cell lines, INCB054329 induces apoptosis consistent with increased expression of pro-apoptotic regulators[2]. INCB054329 reduces expression of Homologous recombination (HR) components and co-operatively reduces cell growth and increases DNA damage and apoptosis induced by cisplatin and PARPi [3]. |
体内活性 | INCB054329 exhibits high clearance in mice leading to a short half-life. At exposures that effectively suppressed c-MYC, INCB054329 is found to be efficacious and well tolerated in both the MM1.S and KMS-12-BM xenograft models[1]. In vivo, oral administration of INCB054329 inhibits tumor growth in several hematologic cancers models[2]. |
细胞实验 | Cell lines: DLBCL, AML, Myeloma cells. Incubation Time: 72 h. Method: Cell viability assay |
动物实验 | Animal Models: KMS-12-BM tumors established in female Nu/Nu mice. Dosages: 3, 10, 30, or 100 mg/kg. Administration: oral gavage. |
别名 | INCB-054329,INCB-54329, INCB-54329 |
分子量 | 348.36 |
分子式 | C19H16N4O3 |
CAS No. | 1628607-64-6 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (287.06 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8706 mL | 14.353 mL | 28.7059 mL | 71.7648 mL |
5 mM | 0.5741 mL | 2.8706 mL | 5.7412 mL | 14.353 mL | |
10 mM | 0.2871 mL | 1.4353 mL | 2.8706 mL | 7.1765 mL | |
20 mM | 0.1435 mL | 0.7176 mL | 1.4353 mL | 3.5882 mL | |
50 mM | 0.0574 mL | 0.2871 mL | 0.5741 mL | 1.4353 mL | |
100 mM | 0.0287 mL | 0.1435 mL | 0.2871 mL | 0.7176 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
INCB054329 1628607-64-6 Chromatin/Epigenetic Epigenetic Reader Domain Inhibitor inhibit INCB 54329 INCB-054329,INCB 54329 INCB-054329,INCB-54329 INCB54329 INCB-054329,INCB54329 INCB-054329 INCB-54329 INCB 054329 inhibitor